Ampio Pharmaceuticals, Inc. (AMPE)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | - USD | 59.45% |
| 2022 | -18.3 Million USD | 3.76% |
| 2021 | - USD | -71.38% |
| 2020 | - USD | 36.68% |
| 2019 | -17.3 Million USD | 59.74% |
| 2018 | 35.26 Million USD | -350.58% |
| 2017 | -14.46 Million USD | 248.45% |
| 2016 | -14.8 Million USD | 53.86% |
| 2015 | -23.34 Million USD | 16.94% |
| 2014 | - USD | -61.82% |
| 2013 | -23.88 Million USD | -103.42% |
| 2012 | -11.75 Million USD | -5.88% |
| 2011 | -11.08 Million USD | -65.36% |
| 2010 | -8.01 Million USD | -30549.19% |
| 2009 | -21.87 Thousand USD | 25.18% |
| 2008 | -29.23 Thousand USD | -9.04% |
| 2007 | -26.8 Thousand USD | -2570.22% |
| 2006 | -1004.00 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 FY | - USD | 59.98% |
| 2023 Q2 | -1.56 Million USD | 62.49% |
| 2023 Q1 | -4.15 Million USD | -43.66% |
| 2023 Q3 | -1.4 Million USD | 10.26% |
| 2023 Q4 | -2.21 Million USD | -58.21% |
| 2022 Q3 | -4.6 Million USD | 39.54% |
| 2022 Q1 | -8.03 Million USD | 32.83% |
| 2022 FY | - USD | 3.76% |
| 2022 Q4 | -2.89 Million USD | 37.15% |
| 2022 Q2 | -7.61 Million USD | 5.24% |
| 2021 Q4 | -11.96 Million USD | -214.12% |
| 2021 Q3 | -3.81 Million USD | -8.39% |
| 2021 Q1 | -3.67 Million USD | -26.19% |
| 2021 Q2 | -3.51 Million USD | 4.38% |
| 2021 FY | - USD | -71.38% |
| 2020 Q2 | -1.62 Million USD | 75.16% |
| 2020 FY | - USD | 36.68% |
| 2020 Q1 | -6.55 Million USD | 49.37% |
| 2020 Q3 | -2.94 Million USD | -80.6% |
| 2020 Q4 | -2.91 Million USD | 0.99% |
| 2019 Q3 | -2.87 Million USD | 59.97% |
| 2019 FY | - USD | 59.74% |
| 2019 Q4 | -12.95 Million USD | -349.85% |
| 2019 Q2 | -7.19 Million USD | -947.65% |
| 2019 Q1 | 848.4 Thousand USD | 113.49% |
| 2018 Q3 | -9.33 Million USD | 11.57% |
| 2018 Q4 | -6.28 Million USD | 32.66% |
| 2018 FY | - USD | -350.58% |
| 2018 Q1 | -28.87 Million USD | -185.37% |
| 2018 Q2 | -10.55 Million USD | 63.43% |
| 2017 Q2 | -6.46 Million USD | -70.43% |
| 2017 FY | - USD | 248.45% |
| 2017 Q4 | 33.81 Million USD | 2246.41% |
| 2017 Q3 | -1.57 Million USD | 75.64% |
| 2017 Q1 | -3.79 Million USD | -69.39% |
| 2016 FY | - USD | 53.86% |
| 2016 Q4 | -2.24 Million USD | 6.13% |
| 2016 Q2 | -4.06 Million USD | 33.59% |
| 2016 Q1 | -6.11 Million USD | 38.76% |
| 2016 Q3 | -2.38 Million USD | 41.24% |
| 2015 Q4 | -9.98 Million USD | -36.49% |
| 2015 Q2 | -7.49 Million USD | -1.66% |
| 2015 Q1 | -7.36 Million USD | 25.79% |
| 2015 Q3 | -7.31 Million USD | 2.32% |
| 2015 FY | - USD | 16.94% |
| 2014 Q2 | -8.89 Million USD | 14.69% |
| 2014 Q4 | -9.92 Million USD | -5.96% |
| 2014 Q3 | -9.37 Million USD | -5.3% |
| 2014 FY | - USD | -61.82% |
| 2014 Q1 | -10.43 Million USD | -39.2% |
| 2013 FY | - USD | -103.42% |
| 2013 Q2 | -6.41 Million USD | -57.85% |
| 2013 Q3 | -5.9 Million USD | 7.98% |
| 2013 Q4 | -7.49 Million USD | -26.95% |
| 2013 Q1 | -4.06 Million USD | -8.8% |
| 2012 Q4 | -3.73 Million USD | -34.48% |
| 2012 FY | - USD | -5.88% |
| 2012 Q3 | -2.77 Million USD | -23.6% |
| 2012 Q2 | -2.24 Million USD | 24.53% |
| 2012 Q1 | -2.97 Million USD | 34.31% |
| 2011 Q4 | -4.53 Million USD | -64.7% |
| 2011 Q1 | 4.29 Million USD | 244.25% |
| 2011 FY | - USD | -65.36% |
| 2011 Q3 | -2.75 Million USD | -726.44% |
| 2011 Q2 | -332.98 Thousand USD | -107.75% |
| 2010 Q1 | -1.47 Million USD | -32427.09% |
| 2010 Q2 | -1.14 Million USD | 22.68% |
| 2010 Q3 | -2.43 Million USD | -112.75% |
| 2010 Q4 | -2.97 Million USD | -22.43% |
| 2010 FY | - USD | -30549.19% |
| 2009 FY | - USD | 25.18% |
| 2009 Q1 | -9704.00 USD | -131.82% |
| 2009 Q4 | -4547.00 USD | -15.11% |
| 2009 Q3 | -3950.00 USD | -7.6% |
| 2009 Q2 | -3671.00 USD | 62.17% |
| 2008 Q2 | -2697.00 USD | 80.03% |
| 2008 Q3 | -6376.00 USD | -136.41% |
| 2008 Q4 | -4186.00 USD | 34.35% |
| 2008 FY | - USD | -9.04% |
| 2008 Q1 | -13.5 Thousand USD | -114.91% |
| 2007 Q4 | -6285.00 USD | 14.2% |
| 2007 Q1 | -300.00 USD | -19.52% |
| 2007 Q2 | -15.09 Thousand USD | -4930.67% |
| 2007 FY | - USD | -2570.22% |
| 2007 Q3 | -7325.00 USD | 51.46% |
| 2006 FY | - USD | 0.0% |
| 2006 Q4 | -251.00 USD | 0.0% |
| 2006 Q3 | -251.00 USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.67 Million USD | 100.0% |
| Armata Pharmaceuticals, Inc. | -39.91 Million USD | 100.0% |
| Actinium Pharmaceuticals, Inc. | -51.13 Million USD | 100.0% |
| Azitra, Inc. | -10.67 Million USD | 100.0% |
| Can-Fite BioPharma Ltd. | -8.18 Million USD | 100.0% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | 100.0% |
| Calidi Biotherapeutics, Inc. | -28.6 Million USD | 100.0% |
| CEL-SCI Corporation | -27.56 Million USD | 100.0% |
| iBio, Inc. | -14.02 Million USD | 100.0% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 100.0% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | 100.0% |
| Matinas BioPharma Holdings, Inc. | -22.82 Million USD | 100.0% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | 100.0% |
| NovaBay Pharmaceuticals, Inc. | -4.8 Million USD | 100.0% |
| NanoViricides, Inc. | -7.75 Million USD | 100.0% |
| Oragenics, Inc. | -20.87 Million USD | 100.0% |
| BiomX Inc. | -22.81 Million USD | 100.0% |
| BiomX Inc. | -22.81 Million USD | 100.0% |
| Protalix BioTherapeutics, Inc. | 11.65 Million USD | 100.0% |
| Palatin Technologies, Inc. | -29.03 Million USD | 100.0% |
| Scorpius Holdings, Inc. | -35.08 Million USD | 100.0% |